SGLT2抑制剂对2型糖尿病患者循环干细胞与祖细胞的影响
本研究通过达格列净与安慰剂随机对照及开放扩展、恩格列净开放观察,评估SGLT2抑制剂对循环干细胞(CSC)和内皮祖细胞(EPC)的影响。12周时达格列净组CSC非显著下降、EPC非显著下降,安慰剂组EPC非显著上升,组间EPC变化有显著差异;开放扩展约1.5年后达格列净组EPC显著增加。结论认为SGLT2抑制剂不显著增加CSC或EPC。
要点
- 达格列净12周组CSC非显著下降,安慰剂组稳定,组间变化无显著差异。
- 达格列净12周组EPC非显著下降,安慰剂组非显著上升,组间变化有显著差异。
- 开放扩展约1.5年后,达格列净组EPC显著增加,CSC保持稳定。
核心结论
- SGLT2抑制剂不显著增加循环干细胞或内皮祖细胞,其心血管保护可能不直接涉及干/祖细胞。
研究设计与样本
- 达格列净10 mg与安慰剂随机对照试验并开放扩展,达格列净组n=31。
- 恩格列净10 mg开放观察性研究,n=15。
- 纳入18至75岁2型糖尿病患者,于三级转诊糖尿病门诊开展。
主要发现
- 12周时达格列净组CSC非显著下降,安慰剂组保持稳定,组间基线变化无显著差异。
- 12周时达格列净组EPC非显著下降,安慰剂组非显著上升,组间基线变化有显著差异。
- 开放扩展约1.5年后,CSC随时间保持稳定,接受达格列净者EPC显著增加。
- 所有患者不论治疗,EPC从基线至观察结束显著增加,同时HbA1c改善。
- 恩格列净开放治疗12周队列中,CSC非显著下降,EPC保持稳定。
临床怎么用
- SGLT2抑制剂对CSC和EPC无显著增加作用,临床心血管获益机制可能不直接经由干/祖细胞。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Reduction in the levels of circulating stem cells (CSCs) and endothelial progenitor cells (EPCs) predicts development or progression of microangiopathy and macroangiopathy in patients with type 2 diabetes (T2D). OBJECTIVE: We tested whether treatment with sodium glucose cotransporter-2 (SGLT2) inhibitors affected the levels of CSCs and EPCs. DESIGN: A randomized trial of dapagliflozin vs placebo with open-label extension, and an open-label observational study of empagliflozin treatment. SETTING: Tertiary referral diabetes outpatient clinic. PATIENTS: Patients with T2D aged 18 to 75 years. INTERVENTION: Dapagliflozin at 10 mg vs placebo (n = 31); empagliflozin at 10 mg (n = 15). MAIN OUTCOME MEASURES: We measured CSCs (CD34+) and EPCs (CD34+KDR+) by flow cytometry at baseline, at 12 weeks, and after the extension period. RESULTS: After 12 weeks, CSCs declined nonsignificantly in the dapagliflozin group, remained stable in the placebo group, and the change from baseline was not significantly different between the two groups. EPCs declined nonsignificantly in the dapagliflozin group, increased nonsignificantly in the placebo group, and the change from baseline was significantly different between the two groups. After an open-label extension period of about 1.5 years, CSCs remained stable over time, whereas EPCs significantly increased in patients who received dapagliflozin. In all patients, irrespectively of treatment, EPCs increased significantly from baseline to the end of observation, concomitantly with improvement in HbA1c. In a cohort of 15 patients who received open-label empagliflozin for 12 weeks, CSCs declined nonsignificantly, whereas EPCs remained stable. CONCLUSION: SGLT2 inhibitors do not significantly increase CSCs or EPCs. Thus, cardiovascular protection by SGLT2 inhibitors may not directly involve stem/progenitor cells.
引用
- Bonora BM, Cappellari R, Albiero M, et al. Effects of SGLT2 Inhibitors on Circulating Stem and Progenitor Cells in Patients With Type 2 Diabetes. J Clin Endocrinol Metab. 2018. PMID: 30113651. doi:10.1210/jc.2018-00824
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。